| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Infections | 13 | 2015 | 78 | 2.220 |
Why?
|
| Anti-Bacterial Agents | 24 | 2022 | 332 | 2.120 |
Why?
|
| Bacterial Proteins | 12 | 2022 | 89 | 1.980 |
Why?
|
| Bacteremia | 8 | 2023 | 65 | 1.940 |
Why?
|
| Methicillin Resistance | 8 | 2023 | 22 | 1.920 |
Why?
|
| Staphylococcus aureus | 10 | 2023 | 54 | 1.880 |
Why?
|
| beta-Lactamases | 6 | 2022 | 13 | 1.860 |
Why?
|
| Klebsiella pneumoniae | 5 | 2020 | 14 | 1.790 |
Why?
|
| Pseudomonas aeruginosa | 5 | 2020 | 35 | 1.690 |
Why?
|
| Bacterial Toxins | 7 | 2015 | 22 | 1.660 |
Why?
|
| Staphylococcus | 4 | 2023 | 10 | 1.600 |
Why?
|
| Meningitis, Meningococcal | 5 | 2010 | 6 | 1.260 |
Why?
|
| Disease Outbreaks | 5 | 2010 | 43 | 1.200 |
Why?
|
| Leukocidins | 5 | 2015 | 5 | 1.160 |
Why?
|
| Cross Infection | 6 | 2012 | 56 | 1.130 |
Why?
|
| Microbial Sensitivity Tests | 17 | 2022 | 79 | 1.120 |
Why?
|
| Polymerase Chain Reaction | 11 | 2021 | 199 | 1.110 |
Why?
|
| Turkey | 21 | 2016 | 25 | 1.090 |
Why?
|
| Exotoxins | 4 | 2015 | 13 | 1.080 |
Why?
|
| Klebsiella Infections | 2 | 2016 | 6 | 0.950 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2016 | 26 | 0.920 |
Why?
|
| Pseudomonas Infections | 2 | 2020 | 14 | 0.900 |
Why?
|
| Vancomycin Resistance | 5 | 2009 | 8 | 0.860 |
Why?
|
| Acinetobacter baumannii | 2 | 2022 | 6 | 0.830 |
Why?
|
| Humans | 50 | 2023 | 32814 | 0.780 |
Why?
|
| Bacterial Typing Techniques | 7 | 2011 | 16 | 0.710 |
Why?
|
| Military Personnel | 5 | 2010 | 103 | 0.710 |
Why?
|
| Blood | 4 | 2011 | 14 | 0.710 |
Why?
|
| Enterococcus faecium | 4 | 2009 | 5 | 0.680 |
Why?
|
| Drug Resistance, Bacterial | 7 | 2020 | 47 | 0.680 |
Why?
|
| Feces | 3 | 2015 | 43 | 0.670 |
Why?
|
| Neisseria meningitidis, Serogroup W-135 | 3 | 2010 | 3 | 0.630 |
Why?
|
| Neisseria meningitidis | 2 | 2010 | 3 | 0.630 |
Why?
|
| Flow Cytometry | 2 | 2016 | 186 | 0.590 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 7 | 2022 | 22 | 0.570 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2015 | 2 | 0.570 |
Why?
|
| Carbapenems | 4 | 2022 | 7 | 0.570 |
Why?
|
| Carbon-Oxygen Ligases | 3 | 2009 | 3 | 0.560 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2009 | 12 | 0.560 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2015 | 34 | 0.550 |
Why?
|
| Chromosomes, Bacterial | 2 | 2008 | 3 | 0.550 |
Why?
|
| Shigella | 1 | 2015 | 8 | 0.480 |
Why?
|
| Male | 29 | 2020 | 19650 | 0.480 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 46 | 0.460 |
Why?
|
| Enterobacteriaceae | 2 | 2015 | 11 | 0.460 |
Why?
|
| Pneumonia | 1 | 2015 | 64 | 0.440 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 6 | 2011 | 11 | 0.440 |
Why?
|
| Bacteriological Techniques | 2 | 2013 | 16 | 0.420 |
Why?
|
| Genotype | 7 | 2010 | 731 | 0.410 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 9 | 0.410 |
Why?
|
| Gram-Positive Bacteria | 1 | 2013 | 3 | 0.400 |
Why?
|
| Root Canal Filling Materials | 1 | 2013 | 3 | 0.400 |
Why?
|
| DNA, Bacterial | 6 | 2015 | 29 | 0.380 |
Why?
|
| Staphylococcus haemolyticus | 1 | 2011 | 2 | 0.360 |
Why?
|
| Staphylococcus epidermidis | 1 | 2011 | 6 | 0.360 |
Why?
|
| Otitis Media with Effusion | 2 | 2008 | 12 | 0.350 |
Why?
|
| Virulence Factors | 2 | 2012 | 10 | 0.350 |
Why?
|
| Female | 20 | 2016 | 20271 | 0.350 |
Why?
|
| Child, Preschool | 5 | 2020 | 1282 | 0.340 |
Why?
|
| beta-Lactam Resistance | 1 | 2011 | 2 | 0.340 |
Why?
|
| DNA, Viral | 2 | 2008 | 54 | 0.340 |
Why?
|
| Salmonella enteritidis | 1 | 2010 | 1 | 0.320 |
Why?
|
| Salmonella Food Poisoning | 1 | 2010 | 1 | 0.320 |
Why?
|
| Helicobacter pylori | 2 | 2009 | 8 | 0.320 |
Why?
|
| Cytomegalovirus | 2 | 2008 | 31 | 0.310 |
Why?
|
| Nose | 1 | 2008 | 12 | 0.290 |
Why?
|
| RNA, Viral | 1 | 2008 | 49 | 0.280 |
Why?
|
| Enterococcus | 2 | 2005 | 11 | 0.280 |
Why?
|
| Acinetobacter | 1 | 2007 | 1 | 0.280 |
Why?
|
| Sphingomonas | 1 | 2007 | 3 | 0.270 |
Why?
|
| Hospital Units | 1 | 2007 | 6 | 0.270 |
Why?
|
| Child | 9 | 2014 | 2478 | 0.270 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2007 | 14 | 0.270 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2007 | 33 | 0.270 |
Why?
|
| Infant, Premature, Diseases | 1 | 2007 | 26 | 0.270 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2006 | 3 | 0.240 |
Why?
|
| Serotyping | 4 | 2010 | 19 | 0.240 |
Why?
|
| Lactams | 1 | 2004 | 1 | 0.220 |
Why?
|
| Adult | 11 | 2020 | 9569 | 0.220 |
Why?
|
| Enterotoxins | 2 | 2015 | 9 | 0.220 |
Why?
|
| Thienamycins | 3 | 2016 | 4 | 0.210 |
Why?
|
| Cerebrospinal Fluid | 4 | 2007 | 18 | 0.200 |
Why?
|
| Escherichia coli | 2 | 2016 | 83 | 0.200 |
Why?
|
| Drug Resistance, Microbial | 1 | 2022 | 14 | 0.190 |
Why?
|
| Dental Cements | 2 | 2013 | 3 | 0.190 |
Why?
|
| Young Adult | 6 | 2014 | 2734 | 0.180 |
Why?
|
| United States | 2 | 2020 | 4109 | 0.180 |
Why?
|
| Hospitals | 2 | 2020 | 109 | 0.170 |
Why?
|
| Immunoassay | 1 | 2021 | 16 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2021 | 23 | 0.170 |
Why?
|
| Ozone | 2 | 2011 | 5 | 0.170 |
Why?
|
| Hyperbaric Oxygenation | 2 | 2011 | 6 | 0.170 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 576 | 0.170 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 2020 | 3 | 0.160 |
Why?
|
| Pancreatitis, Acute Necrotizing | 2 | 2010 | 6 | 0.160 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2020 | 8 | 0.160 |
Why?
|
| Azithromycin | 1 | 2020 | 16 | 0.160 |
Why?
|
| Gonorrhea | 1 | 2020 | 12 | 0.160 |
Why?
|
| Enterococcus faecalis | 2 | 2013 | 12 | 0.160 |
Why?
|
| Atherosclerosis | 1 | 2006 | 788 | 0.160 |
Why?
|
| Hospitals, Military | 2 | 2009 | 11 | 0.150 |
Why?
|
| Carrier State | 2 | 2009 | 23 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 2 | 2010 | 135 | 0.150 |
Why?
|
| DNA Primers | 2 | 2011 | 89 | 0.150 |
Why?
|
| Risk Factors | 3 | 2015 | 3976 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2015 | 4034 | 0.130 |
Why?
|
| Drug Combinations | 2 | 2015 | 99 | 0.130 |
Why?
|
| ROC Curve | 1 | 2016 | 168 | 0.120 |
Why?
|
| Cefoxitin | 1 | 2015 | 1 | 0.120 |
Why?
|
| Oxacillin | 1 | 2015 | 5 | 0.120 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2015 | 3 | 0.120 |
Why?
|
| Phenotype | 3 | 2016 | 638 | 0.120 |
Why?
|
| Brucellosis | 2 | 2006 | 7 | 0.120 |
Why?
|
| Triose-Phosphate Isomerase | 1 | 2015 | 1 | 0.120 |
Why?
|
| ADP Ribose Transferases | 1 | 2015 | 4 | 0.120 |
Why?
|
| Clarithromycin | 1 | 2014 | 1 | 0.110 |
Why?
|
| Viridans Streptococci | 1 | 2014 | 4 | 0.110 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2014 | 2 | 0.110 |
Why?
|
| Bacteria | 2 | 2014 | 55 | 0.110 |
Why?
|
| Tonsillitis | 1 | 2014 | 6 | 0.110 |
Why?
|
| Palatine Tonsil | 1 | 2014 | 8 | 0.110 |
Why?
|
| Candida glabrata | 1 | 2014 | 1 | 0.110 |
Why?
|
| Fungal Proteins | 1 | 2014 | 9 | 0.110 |
Why?
|
| Candidiasis | 1 | 2014 | 6 | 0.110 |
Why?
|
| Methicillin | 2 | 2011 | 4 | 0.110 |
Why?
|
| Enbucrilate | 1 | 2014 | 2 | 0.110 |
Why?
|
| Tissue Adhesives | 1 | 2014 | 7 | 0.110 |
Why?
|
| Culture Media | 2 | 2011 | 45 | 0.100 |
Why?
|
| Air Pollution, Indoor | 1 | 2014 | 10 | 0.100 |
Why?
|
| Aged | 3 | 2015 | 10544 | 0.100 |
Why?
|
| Virulence | 1 | 2013 | 22 | 0.100 |
Why?
|
| Vancomycin | 1 | 2013 | 22 | 0.100 |
Why?
|
| Aerobiosis | 1 | 2013 | 1 | 0.100 |
Why?
|
| Bismuth | 1 | 2013 | 1 | 0.100 |
Why?
|
| Methylmethacrylates | 1 | 2013 | 1 | 0.100 |
Why?
|
| Zinc Oxide-Eugenol Cement | 1 | 2013 | 1 | 0.100 |
Why?
|
| Streptococcus mutans | 1 | 2013 | 4 | 0.100 |
Why?
|
| Silicates | 1 | 2013 | 3 | 0.100 |
Why?
|
| Aluminum Compounds | 1 | 2013 | 4 | 0.100 |
Why?
|
| Hyaluronic Acid | 1 | 2013 | 54 | 0.100 |
Why?
|
| Calcium Compounds | 1 | 2013 | 9 | 0.100 |
Why?
|
| Nerve Regeneration | 1 | 2013 | 49 | 0.100 |
Why?
|
| Metronidazole | 1 | 2013 | 18 | 0.100 |
Why?
|
| Oxides | 1 | 2013 | 18 | 0.100 |
Why?
|
| Temperature | 1 | 2013 | 51 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 118 | 0.100 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 98 | 0.100 |
Why?
|
| Rats | 6 | 2014 | 1606 | 0.100 |
Why?
|
| Materials Testing | 1 | 2013 | 92 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2015 | 2329 | 0.100 |
Why?
|
| Oxidative Stress | 2 | 2011 | 239 | 0.090 |
Why?
|
| Acid Etching, Dental | 1 | 2011 | 1 | 0.090 |
Why?
|
| Orthodontic Brackets | 1 | 2011 | 1 | 0.090 |
Why?
|
| Gingiva | 1 | 2011 | 2 | 0.090 |
Why?
|
| Mutation | 1 | 2014 | 493 | 0.090 |
Why?
|
| Periodontal Diseases | 1 | 2011 | 18 | 0.090 |
Why?
|
| Oxidants, Photochemical | 1 | 2011 | 1 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2010 | 20 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 1012 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 255 | 0.090 |
Why?
|
| Herpesvirus 1, Human | 2 | 2008 | 8 | 0.090 |
Why?
|
| beta-Lactams | 2 | 2016 | 7 | 0.090 |
Why?
|
| Imipenem | 2 | 2016 | 3 | 0.090 |
Why?
|
| Osteomyelitis | 1 | 2011 | 29 | 0.090 |
Why?
|
| Species Specificity | 2 | 2007 | 88 | 0.080 |
Why?
|
| Bacterial Translocation | 1 | 2010 | 9 | 0.080 |
Why?
|
| Prognosis | 3 | 2014 | 1545 | 0.080 |
Why?
|
| Meningococcal Infections | 1 | 2010 | 7 | 0.080 |
Why?
|
| Meningococcal Vaccines | 1 | 2010 | 10 | 0.080 |
Why?
|
| Micrococcal Nuclease | 1 | 2010 | 1 | 0.080 |
Why?
|
| Peptide Elongation Factor Tu | 1 | 2010 | 1 | 0.080 |
Why?
|
| Leptospira | 1 | 2010 | 3 | 0.080 |
Why?
|
| Eggs | 1 | 2010 | 4 | 0.080 |
Why?
|
| Time Factors | 2 | 2013 | 2183 | 0.080 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2010 | 6 | 0.080 |
Why?
|
| Antitubercular Agents | 1 | 2010 | 8 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2010 | 17 | 0.080 |
Why?
|
| Meckel Diverticulum | 1 | 2009 | 1 | 0.080 |
Why?
|
| Gastric Mucosa | 1 | 2009 | 13 | 0.080 |
Why?
|
| Helicobacter Infections | 1 | 2009 | 9 | 0.080 |
Why?
|
| Choristoma | 1 | 2009 | 14 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 30 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2013 | 754 | 0.080 |
Why?
|
| Nasopharynx | 1 | 2009 | 9 | 0.070 |
Why?
|
| Adenovirus Infections, Human | 1 | 2009 | 6 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2009 | 694 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 100 | 0.070 |
Why?
|
| Cerebral Ventricles | 1 | 2008 | 12 | 0.070 |
Why?
|
| Silver | 1 | 2008 | 8 | 0.070 |
Why?
|
| Respiratory Tract Infections | 1 | 2009 | 38 | 0.070 |
Why?
|
| Adenoviridae | 1 | 2009 | 68 | 0.070 |
Why?
|
| Enterovirus | 1 | 2008 | 4 | 0.070 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2008 | 7 | 0.070 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 44 | 0.070 |
Why?
|
| Influenza A virus | 1 | 2008 | 24 | 0.070 |
Why?
|
| Adenoviruses, Human | 1 | 2008 | 28 | 0.070 |
Why?
|
| Melatonin | 1 | 2008 | 4 | 0.070 |
Why?
|
| Genes, Bacterial | 1 | 2008 | 9 | 0.070 |
Why?
|
| Acinetobacter Infections | 1 | 2007 | 3 | 0.070 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2007 | 4 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2007 | 19 | 0.070 |
Why?
|
| Infant, Low Birth Weight | 1 | 2007 | 12 | 0.070 |
Why?
|
| Phylogeny | 1 | 2007 | 62 | 0.070 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2007 | 49 | 0.070 |
Why?
|
| Haemophilus influenzae | 1 | 2007 | 14 | 0.070 |
Why?
|
| Meningitis, Bacterial | 1 | 2007 | 5 | 0.070 |
Why?
|
| Acute Disease | 1 | 2008 | 259 | 0.070 |
Why?
|
| Streptococcus pneumoniae | 1 | 2007 | 40 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 34 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 352 | 0.070 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2007 | 12 | 0.070 |
Why?
|
| Animals | 7 | 2014 | 7570 | 0.060 |
Why?
|
| Tennessee | 1 | 2006 | 107 | 0.060 |
Why?
|
| Brucella | 1 | 2006 | 1 | 0.060 |
Why?
|
| Penicillins | 2 | 2020 | 11 | 0.060 |
Why?
|
| Ceftriaxone | 2 | 2020 | 15 | 0.060 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2006 | 8 | 0.060 |
Why?
|
| Aorta, Abdominal | 1 | 2006 | 29 | 0.060 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2005 | 2 | 0.060 |
Why?
|
| Alprostadil | 1 | 2005 | 3 | 0.060 |
Why?
|
| Bell Palsy | 1 | 2005 | 2 | 0.060 |
Why?
|
| Acyclovir | 1 | 2005 | 14 | 0.060 |
Why?
|
| Carotid Arteries | 1 | 2006 | 101 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 59 | 0.060 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2005 | 14 | 0.060 |
Why?
|
| Piperacillin | 1 | 2004 | 6 | 0.060 |
Why?
|
| Penicillanic Acid | 1 | 2004 | 6 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2006 | 164 | 0.050 |
Why?
|
| Laboratory Infection | 1 | 2004 | 1 | 0.050 |
Why?
|
| Middle Aged | 2 | 2015 | 12133 | 0.050 |
Why?
|
| Oxazolidinones | 1 | 2004 | 1 | 0.050 |
Why?
|
| Virginiamycin | 1 | 2004 | 2 | 0.050 |
Why?
|
| Acetamides | 1 | 2004 | 7 | 0.050 |
Why?
|
| Adolescent | 2 | 2011 | 3640 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2004 | 115 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2006 | 877 | 0.050 |
Why?
|
| Random Allocation | 2 | 2014 | 229 | 0.040 |
Why?
|
| Neopterin | 2 | 2010 | 2 | 0.040 |
Why?
|
| Cefixime | 1 | 2020 | 4 | 0.040 |
Why?
|
| HIV Seronegativity | 1 | 2020 | 8 | 0.040 |
Why?
|
| Amylases | 2 | 2010 | 10 | 0.040 |
Why?
|
| Malondialdehyde | 2 | 2010 | 10 | 0.040 |
Why?
|
| Pharynx | 1 | 2020 | 14 | 0.040 |
Why?
|
| Tetracycline | 1 | 2020 | 13 | 0.040 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 42 | 0.040 |
Why?
|
| Homosexuality, Male | 1 | 2020 | 105 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2014 | 3441 | 0.040 |
Why?
|
| Cefotaxime | 1 | 2015 | 1 | 0.030 |
Why?
|
| Ceftazidime | 1 | 2015 | 1 | 0.030 |
Why?
|
| Clavulanic Acid | 1 | 2015 | 1 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 2016 | 33 | 0.030 |
Why?
|
| Cephalosporins | 1 | 2015 | 9 | 0.030 |
Why?
|
| North Carolina | 1 | 2020 | 1546 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 2285 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2014 | 11 | 0.030 |
Why?
|
| Tonsillectomy | 1 | 2014 | 10 | 0.030 |
Why?
|
| Echinocandins | 1 | 2014 | 6 | 0.030 |
Why?
|
| Drug Resistance, Fungal | 1 | 2014 | 3 | 0.030 |
Why?
|
| Lipopeptides | 1 | 2014 | 6 | 0.030 |
Why?
|
| Infant | 2 | 2009 | 1083 | 0.030 |
Why?
|
| Incidence | 2 | 2009 | 1239 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2014 | 41 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2014 | 79 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 156 | 0.030 |
Why?
|
| Air Pollutants | 1 | 2014 | 23 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 282 | 0.030 |
Why?
|
| Axons | 1 | 2013 | 33 | 0.030 |
Why?
|
| Cicatrix | 1 | 2013 | 39 | 0.030 |
Why?
|
| Schools | 1 | 2014 | 67 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 410 | 0.020 |
Why?
|
| Minisatellite Repeats | 1 | 2012 | 9 | 0.020 |
Why?
|
| Community-Acquired Infections | 1 | 2012 | 32 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 334 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 497 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1002 | 0.020 |
Why?
|
| Composite Resins | 1 | 2011 | 1 | 0.020 |
Why?
|
| Periodontal Pocket | 1 | 2011 | 1 | 0.020 |
Why?
|
| Fusobacterium nucleatum | 1 | 2011 | 1 | 0.020 |
Why?
|
| Dentin-Bonding Agents | 1 | 2011 | 1 | 0.020 |
Why?
|
| Resin Cements | 1 | 2011 | 1 | 0.020 |
Why?
|
| Campylobacter rectus | 1 | 2011 | 1 | 0.020 |
Why?
|
| Curing Lights, Dental | 1 | 2011 | 1 | 0.020 |
Why?
|
| Porphyromonas gingivalis | 1 | 2011 | 2 | 0.020 |
Why?
|
| Prevotella intermedia | 1 | 2011 | 2 | 0.020 |
Why?
|
| Dental Plaque Index | 1 | 2011 | 5 | 0.020 |
Why?
|
| Dental Plaque | 1 | 2011 | 3 | 0.020 |
Why?
|
| Periodontal Index | 1 | 2011 | 6 | 0.020 |
Why?
|
| Gingival Hemorrhage | 1 | 2011 | 4 | 0.020 |
Why?
|
| Bacteroides | 1 | 2011 | 8 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 603 | 0.020 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2010 | 1 | 0.020 |
Why?
|
| Taurocholic Acid | 1 | 2010 | 1 | 0.020 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 2010 | 2 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2010 | 9 | 0.020 |
Why?
|
| Agglutination Tests | 1 | 2010 | 3 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 54 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 82 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2010 | 47 | 0.020 |
Why?
|
| Ethambutol | 1 | 2010 | 1 | 0.020 |
Why?
|
| Streptomycin | 1 | 2010 | 2 | 0.020 |
Why?
|
| RNA, Ribosomal, 23S | 1 | 2010 | 2 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2010 | 10 | 0.020 |
Why?
|
| Rifampin | 1 | 2010 | 8 | 0.020 |
Why?
|
| Isoniazid | 1 | 2010 | 4 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2010 | 32 | 0.020 |
Why?
|
| Cytokines | 1 | 2011 | 247 | 0.020 |
Why?
|
| Pancreas | 1 | 2010 | 103 | 0.020 |
Why?
|
| Ketamine | 1 | 2010 | 19 | 0.020 |
Why?
|
| Lipase | 1 | 2010 | 28 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 163 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 301 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2009 | 44 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2009 | 4 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 2009 | 14 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2009 | 73 | 0.020 |
Why?
|
| Vaccination | 1 | 2010 | 146 | 0.020 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2008 | 7 | 0.020 |
Why?
|
| Equipment Contamination | 1 | 2008 | 12 | 0.020 |
Why?
|
| Intracellular Fluid | 1 | 2008 | 3 | 0.020 |
Why?
|
| Streptogramin B | 1 | 2008 | 1 | 0.020 |
Why?
|
| Lincosamides | 1 | 2008 | 1 | 0.020 |
Why?
|
| Methyltransferases | 1 | 2008 | 6 | 0.020 |
Why?
|
| Erythromycin | 1 | 2008 | 7 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2008 | 81 | 0.020 |
Why?
|
| Clindamycin | 1 | 2008 | 22 | 0.020 |
Why?
|
| Moraxellaceae Infections | 1 | 2007 | 2 | 0.020 |
Why?
|
| Cell Line | 1 | 2009 | 433 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2008 | 33 | 0.020 |
Why?
|
| Haemophilus Infections | 1 | 2007 | 8 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 2007 | 32 | 0.020 |
Why?
|
| Facial Paralysis | 1 | 2005 | 7 | 0.010 |
Why?
|
| Facial Nerve | 1 | 2005 | 4 | 0.010 |
Why?
|
| Drainage | 1 | 2006 | 64 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2005 | 47 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2005 | 42 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2005 | 72 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 767 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 271 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 289 | 0.010 |
Why?
|
| Zoonoses | 1 | 2004 | 6 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 459 | 0.010 |
Why?
|
| Respiratory System | 1 | 2004 | 11 | 0.010 |
Why?
|
| Rectum | 1 | 2004 | 17 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 1461 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2004 | 245 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2009 | 3705 | 0.010 |
Why?
|